- Revenue Cycle Management
- COVID-19
- Reimbursement
- Diabetes Awareness Month
- Risk Management
- Patient Retention
- Staffing
- Medical Economics® 100th Anniversary
- Coding and documentation
- Business of Endocrinology
- Telehealth
- Physicians Financial News
- Cybersecurity
- Cardiovascular Clinical Consult
- Locum Tenens, brought to you by LocumLife®
- Weight Management
- Business of Women's Health
- Practice Efficiency
- Finance and Wealth
- EHRs
- Remote Patient Monitoring
- Sponsored Webinars
- Medical Technology
- Billing and collections
- Acute Pain Management
- Exclusive Content
- Value-based Care
- Business of Pediatrics
- Concierge Medicine 2.0 by Castle Connolly Private Health Partners
- Practice Growth
- Concierge Medicine
- Business of Cardiology
- Implementing the Topcon Ocular Telehealth Platform
- Malpractice
- Influenza
- Sexual Health
- Chronic Conditions
- Technology
- Legal and Policy
- Money
- Opinion
- Vaccines
- Practice Management
- Patient Relations
- Careers
OTC PPIs not likely to increase fracture risk, says FDA
Short-term use of over-the-counter (OTC) proton pump inhibitors (PPIs) probably does not pose an increased risk for hip, spine, and wrist fractures, according to the U.S. Food and Drug Administration (FDA). In May 2010, the FDA announced that PPI labeling would be revised to include a warning about a possible increased risk of fractures.
Short-term use of over-the-counter (OTC) proton pump inhibitors (PPIs) probably does not pose an increased risk for hip, spine, and wrist fractures, according to the U.S. Food and Drug Administration (FDA). In May 2010, the FDA announced that PPI labeling would be revised to include a warning about a possible increased risk of fractures.
Further FDA review of several epidemiologic studies, however, showed that “those at greatest brisk for these fractures received high doses” of PPIs (not available OTC) or used them for 1 year or more. The increased risk of fracture occurred primarily in individuals aged 50 years or older.
